Markets:

Overview

News

Currencies

International

Treasuries

Kiniksa Pharmaceuticals International, plc - Class A Ordinary Shares (NQ:KNSA)

62.83 -0.22 (-0.35%)

Streaming Delayed Price Updated: 10:57 AM EDT, Jul 24, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Kiniksa Pharmaceuticals International, plc - Class A Ordinary Shares

< Previous 1 2 3 4 5 Next >

Danaher Posts Upbeat Earnings, Joins Spotify, MSCI, Owens & Minor And Other Big Stocks Moving Higher On Tuesday ↗

July 23, 2024

Via Benzinga

Sector Spotlight: Orphan Drug Developers With Significant Upside

June 03, 2024

Via AB Newswire

Topics ETFs

Sector Spotlight: Orphan Drug Developers With Significant Upside

June 03, 2024

The biotech sector is finally beginning to recover following a two year stretch of underperformance that was largely driven by rising interest rates and other macro factors. Biotech has a track record...

Via TheNewswire.com

Topics ETFs

KNSA Stock Earnings: Kiniksa Pharmaceuticals Misses EPS, Beats Revenue for Q1 2024 ↗

April 23, 2024

KNSA stock results show that Kiniksa Pharmaceuticals missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.

Via InvestorPlace

Earnings Outlook For Kiniksa Pharmaceuticals ↗

February 27, 2024

Via Benzinga

Earnings Outlook For Kiniksa Pharmaceuticals ↗

October 30, 2023

Via Benzinga

Why Shares of Kiniksa Pharmaceuticals Jumped Tuesday ↗

July 25, 2023

The company reported a big jump in revenue and updated guidance.

Via The Motley Fool

Earnings Scheduled For April 23, 2024 ↗

April 23, 2024

Companies Reporting Before The Bell • RTX (NYSE:RTX) is expected to report quarterly earnings at $1.23 per share on revenue of $18.41 billion.

Via Benzinga

Kiniksa Pharmaceuticals Ltd. (NASDAQ: KNSA) Near the Top of Equities by Percentage Gain on 7/25

July 25, 2023

Via Investor Brand Network

Why Longboard Pharmaceuticals Shares Are Trading Higher By Around 200%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

January 02, 2024

Shares of Longboard Pharmaceuticals, Inc.

Via Benzinga

The 3 Most Undervalued Biotech Stocks to Buy in December ↗

December 15, 2023

Biotech is an increasing area of interest in the financial markets, line your portfolio up with these winning biotech stocks.

Via InvestorPlace

7 Underappreciated Biotech Stocks to Pick Up on the Cheap ↗

November 09, 2023

With questions rising about the economy, investors may consider undervalued biotech stocks for their relative insulation factor.

Via InvestorPlace

Topics Economy

Earnings Outlook For Kiniksa Pharmaceuticals ↗

July 24, 2023

Via Benzinga

Overview Of Value Stocks In The Healthcare Sector ↗

June 05, 2023

Via Benzinga

Amicus Therapeutics Stock Reaches 80+ Relative Strength Benchmark ↗

September 28, 2023

Amicus Therapeutics sees its Relative Strength Rating move into the 80-plus level.

Via Investor's Business Daily

5 Value Stocks In The Healthcare Sector ↗

September 11, 2023

Via Benzinga

5 Value Stocks To Watch In The Healthcare Sector ↗

August 21, 2023

Via Benzinga

Vertex Pharmaceuticals Stock Shows Rising Relative Strength, Hits 80+ ↗

August 16, 2023

Vertex Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 81.

Via Investor's Business Daily

ACELYRIN Stock Scores Relative Strength Rating Upgrade; Hits Key Threshold ↗

August 15, 2023

One key metric to look for in a stock is an 80-plus Relative Strength Rating. ACELYRIN stock hit that mark on Tuesday, with a jump to 81.

Via Investor's Business Daily

Axsome Therapeutics Stock Earns Relative Strength Rating Upgrade ↗

August 15, 2023

A Relative Strength Rating upgrade for Axsome Therapeutics shows improving technical performance.

Via Investor's Business Daily

Exelixis Stock Sees Rising Relative Strength Rating ↗

August 14, 2023

On Monday, Exelixis stock hit an key technical milestone, with its Relative Strength Rating rising to 87, an increase from 79 the day before.

Via Investor's Business Daily

Dynavax Technologies Stock Sees Renewed Technical Strength ↗

August 07, 2023

Dynavax Technologies shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 79 to 84.

Via Investor's Business Daily

Crude Oil Up 1%; Verizon Earnings Beat Views ↗

July 25, 2023

U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 100 points on Tuesday. The Dow traded up 0.28% to 35,510.96 while the NASDAQ rose 0.91% to 14,187.05....

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

July 25, 2023

Via Benzinga

Xerox, Logitech International, Packaging Corporation of America And Other Big Stocks Moving Higher On Tuesday ↗

July 25, 2023

U.S. stocks traded higher, with the Nasdaq Composite gaining around 75 points on Tuesday. Here are some big stocks recording gains in today’s session. Kiniksa Pharmaceuticals, Ltd. (NASDAQ: KNSA)...

Via Benzinga

Why Alaska Air Group Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

July 25, 2023

Gainers Aurora Acquisition Corp. (NASDAQ: AURC) shares jumped 192% to $30.54.

Via Benzinga

5 Value Stocks In The Healthcare Sector ↗

July 24, 2023

Via Benzinga

3 Small-Cap Stocks That Are Worth the Gamble ↗

July 04, 2023

Although these small-cap stock picks may not be household names, they command significant upside potential for daring speculators.

Via InvestorPlace

Abcam Stock Earns Relative Strength Rating Upgrade ↗

June 20, 2023

A Relative Strength Rating upgrade for Abcam ADR shows improving technical performance.

Via Investor's Business Daily

FibroGen Stock Joins Rank Of Stocks With RS Ratings Over 90 ↗

June 06, 2023

On Tuesday, FibroGen stock saw a positive improvement to its Relative Strength Rating, rising to 94 from 90 a day earlier.

Via Investor's Business Daily

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.